Hetrombopag Olamine + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-naive Severe Aplastic Anemia
Conditions
Treatment-naive Severe Aplastic Anemia
Trial Timeline
Sep 19, 2019 → Dec 31, 2024
NCT ID
NCT04961710About Hetrombopag Olamine + Placebo
Hetrombopag Olamine + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Treatment-naive Severe Aplastic Anemia. The current trial status is active. This product is registered under clinical trial identifier NCT04961710. Target conditions include Treatment-naive Severe Aplastic Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04961710 | Phase 3 | Active |